inclusion criteria: * willingness and ability to provide written informed consent * at least 18 and not more than 75 years of age at study entry * sars-cov-2 infection confirmed by pcr test within 4 days before randomization * currently symptomatic (fever or chills, cough, myalgia, sore throat, shortness of breath, or new onset of anosmia or ageusia) and at covid-19 isolation and treatment centre

inclusion criteria: * willingness and ability to provide written informed consent * at least 18 and not more than 75 years of age at study entry * sars-cov-2 infection confirmed by pcr test within 4 days before randomization * currently symptomatic (fever or chills, cough, myalgia, sore throat, shortness of breath, or new onset of anosmia or ageusia) and at covid-19 isolation and treatment centre

inclusion criteria: - willingness and ability to provide written informed consent - at least 18 and not more than 75 years of age at study entry - sars-cov-2 infection confirmed by pcr test within 4 days before randomization - currently symptomatic (fever or chills, cough, myalgia, sore throat, shortness of breath, or new onset of anosmia or ageusia) and at covid-19 isolation and treatment centre

inclusion criteria: - willingness and ability to provide written informed consent - at least 18 and not more than 75 years of age at study entry - sars-cov-2 infection confirmed by pcr test within 4 days before randomization - currently symptomatic (fever or chills, cough, myalgia, sore throat, shortness of breath, or new onset of anosmia or ageusia) and at covid-19 isolation and treatment centre